Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Integrating cutting-edge technologies like AI, machine learning (ML), and deep learning (DL) is expected to overcome the limitations of traditional therapies, achieving more precise and efficient treatment plans
: 2 (10 ) (, )
Many patients read, work on their laptop, or simply relax during their session
Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
US$ 27.33
US$ 21.55
US$ 22.03
US$ 29.60
